Roth Capital Reaffirms Buy Rating for Arch Therapeutics (OTCMKTS:ARTH)

Arch Therapeutics (OTCMKTS:ARTH)‘s stock had its “buy” rating restated by Roth Capital in a report issued on Tuesday, February 5th.

Several other research analysts also recently commented on the company. HC Wainwright set a $3.00 price objective on Arch Therapeutics and gave the stock a “buy” rating in a report on Monday, October 8th. Zacks Investment Research cut Arch Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 29th. Finally, Ifs Securities upgraded shares of Arch Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Friday, February 1st. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $1.75.

Shares of ARTH stock traded up $0.01 on Tuesday, reaching $0.39. The company’s stock had a trading volume of 87,708 shares, compared to its average volume of 264,652. Arch Therapeutics has a 12-month low of $0.26 and a 12-month high of $0.69.

About Arch Therapeutics

Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures.

Recommended Story: What is a recession?

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply